BofA raised the firm’s price target on Align Technology to $215 from $180 and keeps an Underperform rating on the shares after the company reported Q4 sales 2% ahead of consensus and adjusted EPS that was 11% ahead. While the Q4 result and initial 2024 guidance was better than some had expected, the firm notes that its model remains largely unchanged and it doesn’t believe there’s enough evidence that Align can return to the high level of growth and profitability from prior years.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALGN:
- Options Volatility and Implied Earnings Moves Today, January 31, 2024
- ALGN Earnings this Week: How Will it Perform?
- Align Technology price target raised to $285 from $250 at Stifel
- Align Technology put volume heavy and directionally bearish
- Align receives FDA 510(k) clearance for Invisalign Palatal Expander System